Table 1 Demographics of patients with central serous chorioretinopathy and their previous treatments

Age (years)

55.61 ± 2.32 (45–71 years)

Sex (male/female)

13/0

Duration of CSCR symptoms prior to eplerenone therapy (months)

17.40 ± 3.9 (4–36 months)

Total number of patients with prior treatments

5/13^a

 Photodynamic laser therapy (PDT)

3/13

 Focal laser therapy

2/13

 Intravitreal bevacizumab

3/13